Cefotetan: a Second-generation Cephalosporin Active Against Anaerobic Bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society

Overview

Journal CMAJ

Date 1994 Sep 1

PMID 8069799

Authors

M J Gribble

Affiliations

Soon will be listed here.

Abstract

Objective: To offer guidelines for the use of cefotetan, a cephamycin antibiotic, in order to minimize its overprescription.

Options: Clinical practice options considered were treatment of infections with the use of second- and third-generation cephalosporins, carbapenems such as imipenem as well as combination regimens of agents active against anaerobic bacteria, such as metronidazole or clindamycin with an aminoglycoside.

Outcomes: In order of importance: efficacy, side effects and cost.

Evidence: A MEDLINE search of articles published between January 1982 and December 1993. In-vitro and pharmacokinetic studies published in recognized peer-reviewed journals that used recognized standard methods with appropriate controls were reviewed. For results of clinical trials, the reviewers emphasized randomized double-blind trials with appropriate controls.

Values: The Antimicrobial Agents Committee of the Canadian Infectious Disease Society (CIDS) and a recognized expert (M.J.G.) recommended use of cefotetan to prevent and treat infections against which it has proved effective in randomized controlled trials.

Benefits, Harms And Costs: These guidelines should lead to less inappropriate prescribing of cefotetan, with its attendant costs and risk of development of resistant bacteria.

Recommendations: Cefotetan could be considered an alternative single agent for prophylaxis of infection in patients undergoing elective bowel surgery. It may be used to treat patients with acute pelvic inflammatory disease and endometritis.

Validation: This article was prepared, reviewed and revised by the Committee on Antimicrobial Agents of the CIDS. It was then reviewed by the Council of the CIDS, and any further necessary revisions were made by the chairman of the committee.

References

Ayers L, Jones R, Barry A, Thornsberry C, Fuchs P, Gavan T . Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother. 1982; 22(5):859-77. PMC: 185673. DOI: 10.1128/AAC.22.5.859. View

Kaiser C, McAuliffe J, Barth R, Lynch J . Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. Arch Surg. 1991; 126(4):524-5. DOI: 10.1001/archsurg.1991.01410280128021. View

Ambrose N, Johnson M, Burdon D, Keighley M . The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother. 1985; 15(3):319-26. DOI: 10.1093/jac/15.3.319. View

Drumm J, Donovan I, Wise R . A comparison of cefotetan and cephazolin for prophylaxis against wound infection after elective cholecystectomy. J Hosp Infect. 1985; 6(3):277-80. View

Ward A, Richards D . Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30(5):382-426. DOI: 10.2165/00003495-198530050-00002. View

Dias M, Jacobus N, Tally F, Gorbach S . Activity of cefotetan against anaerobic bacteria. Diagn Microbiol Infect Dis. 1986; 4(4):359-63. DOI: 10.1016/0732-8893(86)90079-9. View

Leaper D, Cooper M, Turner A . A comparative trial between cefotetan and cephazolin for wound sepsis prophylaxis during elective upper gastrointestinal surgery with an investigation of cefotetan penetration into the obstructed biliary tree. J Hosp Infect. 1986; 7(3):269-76. DOI: 10.1016/0195-6701(86)90077-0. View

Smith B, LeFrock J, THYRUM P, Doret B, Yeh C, Onesti G . Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother. 1986; 29(5):887-93. PMC: 284173. DOI: 10.1128/AAC.29.5.887. View

Browning M, HOLT H, White L, Chapman S, Banks R, Reeves D . Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis. J Antimicrob Chemother. 1986; 18(1):103-6. DOI: 10.1093/jac/18.1.103. View

10.

Barry A, Jones R . Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J Clin Microbiol. 1987; 25(8):1570-1. PMC: 269276. DOI: 10.1128/jcm.25.8.1570-1571.1987. View

11.

Conjura A, Bell W, Lipsky J . Cefotetan and hypoprothrombinemia. Ann Intern Med. 1988; 108(4):643. DOI: 10.7326/0003-4819-108-4-643_1. View

12.

Holt J . Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients. Arch Surg. 1988; 123(4):523. DOI: 10.1001/archsurg.1988.01400280137028. View

13.

McGregor J, Gordon S, Krotec J, Poindexter A . Results of a randomized, multicenter, comparative trial of a single dose of cefotetan versus multiple doses of cefoxitin as prophylaxis in cesarean section. Am J Obstet Gynecol. 1988; 158(3 Pt 2):701-6. DOI: 10.1016/s0002-9378(16)44530-8. View

14.

Berkeley A, Freedman K, Ledger W, Orr J, BENIGNO B, Gordon S . Comparison of cefotetan and cefoxitin prophylaxis for abdominal and vaginal hysterectomy. Am J Obstet Gynecol. 1988; 158(3 Pt 2):706-9. DOI: 10.1016/s0002-9378(16)44531-x. View

15.

Hemsell D, Wendel G, Gall S, Newton E, Gibbs R, Knuppel R . Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. Am J Obstet Gynecol. 1988; 158(3 Pt 2):722-7. DOI: 10.1016/s0002-9378(16)44535-7. View

16.

Lewis R, DUMA R, Echols R, Jemsek J, Najem A, Press R . Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections. Am J Obstet Gynecol. 1988; 158(3 Pt 2):728-35. DOI: 10.1016/s0002-9378(16)44536-9. View

17.

Sweet R, Schachter J, Landers D, Robbie M . Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline. Am J Obstet Gynecol. 1988; 158(3 Pt 2):736-41. DOI: 10.1016/s0002-9378(16)44537-0. View

18.

Fry D . Cefotetan: a perspective for the surgical patient. Am J Surg. 1988; 155(5A):108-10. DOI: 10.1016/s0002-9610(88)80225-3. View

19.

Jones R . Cefotetan: a review of the microbiologic properties and antimicrobial spectrum. Am J Surg. 1988; 155(5A):16-23. DOI: 10.1016/s0002-9610(88)80207-1. View

20.

Barry A . Criteria for in vitro susceptibility testing of cefotetan. Correlations with clinical and bacteriologic responses. Am J Surg. 1988; 155(5A):24-9. DOI: 10.1016/s0002-9610(88)80208-3. View